Pulmatrix (NASDAQ:PULM) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Pulmatrix (NASDAQ:PULM) in a note issued to investors on Monday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Pulmatrix Stock Up 39.6 %

Shares of NASDAQ PULM opened at $6.56 on Monday. Pulmatrix has a twelve month low of $1.55 and a twelve month high of $7.87. The company has a 50 day moving average of $2.25 and a 200 day moving average of $2.10. The firm has a market cap of $23.96 million, a P/E ratio of -2.48 and a beta of 0.99.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.